# Nuclide record nct07590934 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct07590934/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct07590934", "NCT07590934" ;
  schema:name "Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer"@en ;
  schema:alternateName "PROSPECTOR"@en ;
  schema:description "A phase 1/2 trial of FPI-2265, Actinium-225 PSMA agents, Palacaparib in prostate cancer, run by AstraZeneca, now recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct07590934/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07590934> ;
  nuclide:status "recruiting" ;
  nuclide:tag "ctgov-ingest" ;
  nuclide:phase "1/2" ;
  nuclide:related <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/> ;
  nuclide:drugs <https://nuclide.cc/drugs/fpi-2265/>, <https://nuclide.cc/drugs/ac225-psma/>, <https://nuclide.cc/drugs/docetaxel/> ;
  nuclide:companies <https://nuclide.cc/companies/astrazeneca/> .